Showing results (61-70 of 124) with videos related to
Sort By:
Pageof 13
Bone Marrow Transplantation|February 21, 2024
Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparisonDietrich Wilhelm Beelen, Simona Iacobelli, Linda Koster, et al.Bone Marrow Transplantation|March 31, 2023
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMTGesine Bug, Myriam Labopin, Riitta Niittyvuopio, et al.Bone Marrow Transplantation|December 6, 2025
Reduced intensity conditioning with 8 Gy total body irradiation in adult patients with acute lymphoblastic leukemiaKlaus Wethmar, Matthias Edinger, Kerstin Schäfer-Eckart, et al.Transplantation and Cellular Therapy|March 17, 2022
High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study GroupJudith Schaffrath, Christina Brummer, Daniel Wolff, et al.Bone Marrow Transplantation|November 22, 2025
Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMTKordelia Barbullushi, Myriam Labopin, Nicolaus Kröger, et al.Bone Marrow Transplantation|March 30, 2024
Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)Enrico Maffini, Myriam Labopin, Nicolaus Kröger, et al.Oncology Research and Treatment|January 10, 2024
Management of Patients Undergoing CAR-T Cell Therapy in GermanyOlaf Penack, Peter Dreger, Salem Ajib, et al.Hemasphere|October 23, 2024
Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemiaMarion Larue, Myriam Labopin, Thomas Schroeder, et al.BMJ Open|June 1, 2022
Web-based mindfulness and skills-based distress reduction for patients with cancer: study protocol of the multicentre, randomised, controlled confirmatory intervention trial ReductAlexander Bäuerle, Peter Martus, Yesim Erim, et al.Journal of Hematology & Oncology|August 16, 2023
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual diseaseJonas S Heitmann, Richard F Schlenk, Daniela Dörfel, et al.Pageof 13